Found: 7
Select item for more details and to access through your institution.
RAF inhibitors that evade paradoxical MAPK pathway activation.
- Published in:
- Nature, 2015, v. 526, n. 7574, p. 583, doi. 10.1038/nature14982
- By:
- Publication type:
- Article
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
- Published in:
- Neuro-Oncology, 2016, v. 18, n. 4, p. 557, doi. 10.1093/neuonc/nov245
- By:
- Publication type:
- Article
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919854238
- By:
- Publication type:
- Article
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919854238
- By:
- Publication type:
- Article
Renal calcium oxalate binding protein: Studies on its properties.
- Published in:
- Kidney International, 1998, v. 53, n. 1, p. 125, doi. 10.1046/j.1523-1755.1998.00740.x
- By:
- Publication type:
- Article
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
- Published in:
- Nature, 2010, v. 467, n. 7315, p. 596, doi. 10.1038/nature09454
- By:
- Publication type:
- Article
ERβ Binds N-CoR in the Presence of Estrogens via an LXXLL-like Motif in the N-CoR C-terminus.
- Published in:
- Nuclear Receptor, 2003, v. 1, p. 4, doi. 10.1186/1478-1336-1-4
- By:
- Publication type:
- Article